Wesco Aircraft Holdings, Inc. (NYSE:WAIR) last session’s volume of 0.87 million shares was higher than its average volume of 0.69 million shares. The stock, after opening at $8.85, hit $9.05 through the close by scoring 1.69%.Wesco Aircraft Holdings, Inc. (WAIR) Analyst Opinion
Wesco Aircraft Holdings, Inc. has a consensus underperform rating from 8 Wall Street analysts, and the number of shares currently sold short amount to at least 3.87% of shares outstanding. The stock sank -23.31% last month and is down -39.46 this year. Wall Street is only getting more bearish on the stock, with 1 of analysts who cover WAIR having a buy-equivalent rating. Analysts have placed a $9.75 price target on Wesco Aircraft Holdings, Inc., suggesting a 7.73% gain from recent close. It’s currently trading about -42.65% below its 52-week high.Wesco Aircraft Holdings, Inc. Earnings Surprise
Wesco Aircraft Holdings, Inc. (WAIR) failed to surprise the stock market in its last reported earnings when it earned $0.21 a piece versus the consensus-estimated $0.26. Its revenue totaled $378.5 million up 11.53% from the previous quarter.
This stock (WAIR) is ahead of its 52-week low with 21.31%. Its last month’s stock price volatility remained 4.92% which for the week stands at 4.26%. The share price has moved backward from its 20 days moving average, trading at a distance of -10.73% and stays -17.73% away from its 50 days moving average. Over the last five days, shares have managed 7.1% gains and now is down -31.2% since hitting its 200-day moving average of $13. Wesco Aircraft Holdings, Inc. (WAIR) has made its way to a 12-month decline of -35.95%.
Turning to Regenxbio Inc. (NASDAQ:RGNX), its shares were trading at $19.05 a gain of $0.8, on the trading floor. The stock, after opening at $18.3, touched a high of $19.25 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.8. Regenxbio Inc. has 1 buy ratings, 0 holds and 0 sells even after the stock tumbled -22.4% from its high of $24.55 to a $566.55 million market value through last close.Regenxbio Inc. (RGNX) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 1.75 to 1.75 during a month. Analysts set a 12-month price target of $34 a share. The target implies a 78.48% spike from where the shares are currently trading. Also, the current price highlights a discount of 162.47% to analysts’ high consensus price target.Regenxbio Inc. (NASDAQ:RGNX) Intraday Trading
The counter witnessed a trading volume of 0.19 million shares versus an average volume of 0.31 million shares during last trading session. Its last month’s stock price volatility remained 5.9% which for the week approaches 5.97%. The lowest price the stock reached in the last trading day was $17.67 and compares with the $7.07 52-week low. The stock recovered 169.45% since its low point and has performed 2.7% year-to-date.